<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257851</url>
  </required_header>
  <id_info>
    <org_study_id>DTH: 20001</org_study_id>
    <nct_id>NCT04257851</nct_id>
  </id_info>
  <brief_title>Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache</brief_title>
  <official_title>Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour Teaching Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To compare the safety and efficacy of oral theophylline versus oral sumatriptan&#xD;
      in the treatment of post-dural puncture headache (PDPH).&#xD;
&#xD;
      Background: PDPH is the most frequent complication of procedures associated with dural&#xD;
      puncture for spinal anesthesia or following accidental dural puncture during epidural&#xD;
      anesthesia. Since invasive treatments have known complications, pharmacologic management may&#xD;
      be preferable.&#xD;
&#xD;
      Patients and Methods: This was a prospective, randomized, double-blind, phase four clinical&#xD;
      trial; carried out on 60 patients presented with PDPH at our hospital. Patients were randomly&#xD;
      allocated into two equal groups (30 patients each); group T, received oral theophylline, and&#xD;
      group S, received oral sumatriptan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 15, 2020</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">May 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median and Range of Numeric Pain Rating Scale (NPRS) score [(median (range)]</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>NPRS measures the severity of PDPH, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain (before, 2h, 6h, 12h, 18h, 24h, then every 12h till 48h)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean and Standard deviation of Numeric Pain Rating Scale (NPRS) score (mean±SD)</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>NPRS measures the severity of PDPH, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain (before, 2h, 6h, 12h, 18h, 24h, then every 12h till 48h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean and Standard deviation of PDPH duration (hours) (mean±SD)</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>Time from PDPH onset till NPRS score ≤ 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean and Standard deviation of Length of hospital stay (days) (mean±SD)</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>Time from hospital admission till discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants and Rate of Treatment-related side effects</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>Number of participants and Rate of: Palpitation, Dizziness, Gastric irritation, Nausea/Vomiting, Diarrhea, Warm sensations in the body, Tingling sensation, and Tightness in the chest, throat, neck, or jaws.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Post-Dural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>Group T (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Theophylline group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sumatriptan group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline Anhydrous Oral Tablet</intervention_name>
    <description>Theophylline tablet (150 mg/12h)</description>
    <arm_group_label>Group T (n=30)</arm_group_label>
    <other_name>Quibron-T/SR tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan Succinate Oral Tablet</intervention_name>
    <description>Sumatriptan tablet (25 mg/12h)</description>
    <arm_group_label>Group S (n=30)</arm_group_label>
    <other_name>Sumigran tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with NPRS score of ≥ 5&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status ≤ II&#xD;
&#xD;
          -  Age from 21 to 50 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with NPRS score &lt; 5&#xD;
&#xD;
          -  ASA physical status &gt; II&#xD;
&#xD;
          -  Age &lt; 21 years or &gt; 50 years&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  History of; Chronic headache, Cluster headache, Migraine&#xD;
&#xD;
          -  History of; Convulsions, Cerebrovascular accident, Previous neurological diseases&#xD;
&#xD;
          -  History of peripheral vascular disease (ischemic colitis)&#xD;
&#xD;
          -  Signs of meningismus&#xD;
&#xD;
          -  Dysrhythmia&#xD;
&#xD;
          -  Hypertension&#xD;
&#xD;
          -  Ischemic heart disease&#xD;
&#xD;
          -  Hyperthyroidism&#xD;
&#xD;
          -  Liver or Renal impairment&#xD;
&#xD;
          -  Use of selective serotonin reuptake inhibitors (SSRIs)&#xD;
&#xD;
          -  Use of ergotamine derivatives in the past 24 hours&#xD;
&#xD;
          -  Use of monoamine oxidase inhibitors (MAOIs) in the last two weeks&#xD;
&#xD;
          -  Use of any kind of opiates&#xD;
&#xD;
          -  Allergy to the study medications&#xD;
&#xD;
          -  Any contraindication of oral intake&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Shaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damanhour Teaching Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Damanhour Teaching Hospital</name>
      <address>
        <city>Damanhūr</city>
        <state>El-Beheira</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-dural puncture headache</keyword>
  <keyword>Spinal anesthesia</keyword>
  <keyword>Sumatriptan</keyword>
  <keyword>Theophylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

